A randomized study comparing cyclophosphamide, doxorubicin, vincristine (CAV) with cyclophosphamide, etoposide, vincristine, methotrexate (CEVM) in patients with small cell lung cancer
Küçük Resim Yok
Tarih
1993
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Taylor and Francis Online
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
This trial was carried out to assess the response rate and survival benefit achieved, if any, by substitution of etoposide for doxorubicin and addition of methotrexate in combination with cyclophosphamide and vincristine in the treatment of 113 patients with small cell lung carcinoma (SCLC). Cyclophosphamide, etoposide, vincristine, methotrexate (CEV-M) yielded a response rate of 75% in localized disease (LD) and 63% in extensive disease (ED), versus 61% in LD and 52% in ED in the cyclophosphamide, doxorubicin, vincristine (CAV) arm. There was also a significant survival benefit for the respondera in favor of CEV-M (21.7±3.8 months of median survival compared to 13.6±2.8 months in CAV arm) in patients with LD.
Açıklama
Anahtar Kelimeler
Chemotherapy, Cell lung cancer, Etoposide
Kaynak
Journal of Chemotherapy
WoS Q Değeri
Scopus Q Değeri
Cilt
5
Sayı
1
Künye
Erkişi, M., Ünsal, M., Tınalı, C. ve Doran, F. (1994). A randomized study comparing cyclophosphamide, doxorubicin, vincristine (CAV) with cyclophosphamide, etoposide, vincristine, methotrexate (CEVM) in patients with small cell lung cancer. Journal of Chemotherapy. 5(1), s. 56-59.
